Cytokine receptors associated with myelogenous haematological proliferative disorders and uses thereof

• US 8,709,715 B2
• Filed: 03/26/2009
• Issued: 04/29/2014
• Est. Priority Date: 03/26/2008
• Status: Active Grant

• Current Assignee: Cantargia AB
• Original Assignee: Cellerant Therapeutics Incorporated
• Inventors: Karsunky, Holger
• Primary Examiner(s): Ketter, Jim
• Assistant Examiner(s): Ghafoorian, Reza
• Application Number:
  US12/934,120
• Publication Number:
  US 20110059852A1
• Time in Patent Office: 1,860 Days
• Field of Search: None
• US Class Current: 435/6.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 39/39558 against tumor tissues, cells, antigens
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: C07K 16/28 against receptors, cell surface antigens or cell surface determinants
• CPC Class Codes: C07K 16/2866 against receptors for cytokines, lymphokines, interferons
• CPC Class Codes: C07K 2317/73 Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
• CPC Class Codes: G01N 2333/726 G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
• CPC Class Codes: G01N 2800/52 Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
• CPC Class Codes: G01N 33/56966 Animal cells
• CPC Class Codes: G01N 33/57426 leukemia
• CPC Class Codes: Y10T 436/143333 Saccharide [e.g., DNA, etc.]

Abstract

The disclosure relates to methods and compositions effective in the diagnosis, prognosis and treatment of human hematopoietic cancers. In particular, the disclosure provides tumor-associated genes that encode for cytokine receptors that are differentially expressed in hematopoietic tumor cells of myeloid origin compared with other cells, e.g., normal stem cells.

Claims

1. A method of monitoring the efficacy of treating acute myelogenous leukemia (AML) in a patient, comprising

obtaining a test sample from said patient at two or more time points during said treatment of AML, wherein the test sample is a blood sample

detecting a level of an expression product corresponding to interleukin 1 receptor accessory protein (IL1RAP) in CD34+ cells in each of the test samples, and

determining that the patient has a positive response to treatment of AML when the level in the levels of said expression product are reduced over time.

2. The method of claim 1, wherein said expression product is mRNA.

3. The method of claim 1, wherein the levels of at least two different expression products are detected at two or more of said time points.

4. The method of claim 1, wherein said detecting uses a microarray.

5. The method of claim 1, wherein the expression product is protein.

6. The method of claim 5, wherein the detecting comprises use of an antibody.